Skip to main content
. 2015 Jul 14;4(3):283–296. doi: 10.1007/s40121-015-0075-9

Table 2.

Demographic and clinical characteristics (safety population)

Characteristics Patients treated with daptomycin
RIE
N = 149
LIE
N = 414
BRLIE
N = 47
Age (years)
 Median (range) 58.0 (1–90) 62.0 (10–91) 63.0 (24–87)
 <65, n (%) 93 (62.4) 227 (54.8) 25 (53.2)
 ≥65, n (%) 56 (37.6) 187 (45.2) 22 (46.8)
 ≥75, n (%) 28 (18.8) 82 (19.8) 16 (34.0)
Sex, n (%)
 Female 45 (30.2) 154 (37.2) 17 (36.2)
 Male 104 (69.8) 260 (62.8) 30 (63.8)
Race, n (%)
 Caucasian 124 (83.2) 355 (85.7) 40 (85.1)
 Othera 14 (9.4) 28 (6.8) 2 (4.3)
 Unknown 11 (7.4) 31 (7.5) 5 (10.6)
Body weight (kg)
 Median (range) 68.0 (6–98) 73.0 (25–120) 70.0 (43–93)
Setting prior to daptomycin therapy, n (%)
 Hospital 133 (89.3) 389 (94.0) 43 (91.5)
 Nursing home/extended care 1 (2.1)
 Community 14 (9.4) 24 (5.8) 2 (4.3)
 Unknown 1 (2.1)
 Other 2 (1.3) 1 (0.2)
Received HMG-CoA reductase inhibitor (statin) with daptomycin, n (%)
 Yes 19 (12.8) 59 (14.3) 3 (6.4)
 No 129 (86.6) 354 (85.5) 44 (93.6)
 Unknown 1 (0.7) 1 (0.2)
Severe renal impairment (CrCl <30 mL/min) at initiation of daptomycin therapy, n (%) 18 (12.1) 76 (18.4) 8 (17.0)
Patients on dialysis at daptomycin initiation, n (%) 13 (8.7) 51 (12.3) 6 (12.8)
Any significant underlying diseases (>10% of patients in every group), n (%) 133 (89.3) 378 (91.3) 43 (91.5)
 Cardiovascular disease 93 (62.4) 322 (77.8) 34 (72.3)
 Gastrointestinal disease 24 (16.1) 55 (13.3) 7 (14.9)
 Pulmonary disease 21 (14.1) 51 (12.3) 9 (19.1)
 Renal disease 25 (16.8) 83 (20.0) 12 (25.5)

BRLIE both right- and left-sided infective endocarditis, CrCl creatinine clearance, HMG-CoA 3-hydroxy-3-methylglutaryl-coenzyme A, LIE left-sided infective endocarditis, RIE right-sided infective endocarditis, SD standard deviation

aAsian, Black and missing